Ratings by JPMorgan (Hardik Parikh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Pacira Pharmaceuticals | PCRX | Upgrade | Neutral (Underweight) |
25.20 (36.34) |
44.21% | Details | |
| 10/1/2026 | Spyre | SYRE | New Coverage | Overweight (N/A) |
84.72 (79.90) |
-5.69% | Details | |
| 8/11/2026 | Viking Therapeutics | VKTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Kailera Therapeutics | KLRA | New Coverage | Overweight (N/A) |
21.47 (11.25) |
-47.6% | Details | |
| 1/22/2026 | Structure Therapeutics | GPCR | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/24/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2025 | Viking Therapeutic | VKTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Underweight (Underweight) |
|
Details | ||
| 2/19/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Underweight (N/A) |
|
Details | ||
| 9/11/2024 | Viking Therapeutic | VKTX | New Coverage | Overweight (N/A) |
54.78 (25.17) |
-54.05% | Details | |
| 8/12/2024 | Pacira Pharmaceuticals | PCRX | Downgrade | Underweight (Overweight) |
22.36 (25.20) |
12.7% | Details | |
| 5/21/2024 | Structure Therapeutics | GPCR | New Coverage | Overweight (N/A) |
36.15 (21.08) |
-41.69% | Details | |
| 3/7/2024 | Pacira Pharmaceuticals | PCRX | New Coverage | Overweight (N/A) |
29.44 (22.36) |
-24.05% | Details |
